Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
10.9M
-
Shares change
-
-26.9K
-
Total reported value, excl. options
-
$62.4M
-
Value change
-
-$154K
-
Number of sells
-
-1
-
Price
-
$5.71
Significant Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q4 2023
3 filings reported holding ABCL - AbCellera Biologics Inc. - Ordinary Shares as of Q4 2023.
AbCellera Biologics Inc. - Ordinary Shares (ABCL) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.9M shares
of 293M outstanding shares and own 3.73% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (24M shares), BAKER BROS. ADVISORS LP (22.9M shares), Voya Investment Management LLC (10.6M shares), Capital World Investors (8.35M shares), CREDIT SUISSE AG/ (4.58M shares), ORBIMED ADVISORS LLC (4.18M shares), ArrowMark Colorado Holdings LLC (4.11M shares), BlackRock Inc. (3.91M shares), Founders Fund VII Management, LLC (3.77M shares), and LAZARD ASSET MANAGEMENT LLC (3.41M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.